Effect of CYP3A5 Genotype on Renal Allograft Recipients Treated With Tacrolimus

Transplantation Proceedings

Volumn 41, Issue 5, 2009, Pages 1557-1561

  Chen, J S ^a   Li, L S ^a   Cheng, D R ^a   Ji, S M ^a   Sun, Q Q ^a   Cheng, Z ^a   Wen, J Q ^a   Sha, G Z ^a   Liu, Z H ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYTOCHROME P450 3A5; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL EVALUATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DNA POLYMORPHISM; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; GENOTYPE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY FIBROSIS; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; SCHOOL CHILD; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CADAVER; CHILD; CREATININE; CYTOCHROME P-450 CYP3A; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; KIDNEY TUBULES; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; TACROLIMUS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 67249155347     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2009.01.097     Document Type: Article

References (17)

1. Lampen A., Christians U., Guengerich F.P., et al. Metabolism of the immunosuppressant tacrolimus in the small intestine:cytochrome P450 drug interactions, and interindividual variability. Drug Metab Dispos 23 (1995) 1315
2. Sattler M., Guengerich F.P., Yun C.H., et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of tacrolimus and rapamycin in males and rat. Drug Metab Dispos 20 (1992) 753
3. Ninova D., Covarrubias M., Rea D.J., et al. acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: differential intragraft expression of transforming growth factor-B1 and a-smooth muscle actin. Transplantation 78 (2004) 338
4. Zhang X., Liu Z.H., Zheng J.M., et al. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation. Clin Transplant 19 (2005) 638
5. Tada H., Tsuchiya N., Satoh S., et al. Impact of CYP3A5 and MDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant Proc 37 (2005) 1730
6. Zhao Y., Song M., Guan D., et al. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. Transplant Proc 37 (2005) 178
7. Racusen L.C., Solez K., Colvin R.B., et al. The Banff97 working classification for renal allograft pathology. Kidney Int 55 (1999) 713
8. Ninova D., Covarrubias M., Rea D.J., et al. Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: differential intragraft expression of transforming growth factor-β1 and α-smooth muscle actin. Transplantation 78 (2004) 338
9. Venkataramanan R., Swaminathan A., Prasad T., et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 29 (1995) 404
10. Wallemacq P.E., and Verbeeck P.K. Comparative clinical pharmacokimetics of tacrolimus in paediatric and adult patients. Clin Pharmacokinet 40 (2001) 283
11. Mancinelli L.M., Frassetto L., Floren L.C., et al. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 69 (2001) 24
12. Tuteja S., Alloway R.R., Johnson J.A., et al. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation 71 (2001) 1303
13. Thervet E., Anglicheau D., King B., et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 76 (2003) 1233
14. Zheng H., Zeevi A., Schuetz E., et al. Tacrolimus dosing in adult lung transplant patients is related to cytochrome p4503A5gene polymorphism. J Clin Pharmacol 44 (2004) 135
15. Haufroid V., Mourad M., Van Kerckhove V., et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 14 (2004) 147
16. Facund C., Diaz J.M., Guirado L., et al. Results of a triple induction regime with tacrolimus, mycophenolate mofetil, and prednisone in renal transplantation. Transplant Proce 34 (2002) 98
17. Demirbas A., Tuncer M., Yavuz A., et al. Influence of tacrolimus plus mycophenolate mofetil regimens on acute rejection rate and diabetes mellitus development in renal transplant recipients. Transplant Proce 36 (2004) 177